




PHARMACEUTICAL 2019

Akebia Therapeutics Inc.
Rank 135 of 363





PHARMACEUTICAL 2019

Akebia Therapeutics Inc.
Rank 135 of 363

Akebia

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 103% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	468,275
Cost of Goods Sold	7,768
Intangible Assets	55,053
Liabilities, Current	265,693
Liabilities, Non-Current	85,282
Other Assets	465,189
Other Compr. Net Income	181
Other Expenses	-28,271
Other Liabilities	9,637
Other Net Income	6,235
Other Revenues	207,742
Property and Equipment	8,023
Research and Development	291,007
Selling, General and Administrative Expense	87,061

Output Variable	Value in 1000 USD
Assets	996,540
Liabilities	360,612
Expenses	357,565
Revenues	207,742
Stockholders Equity	635,928
Net Income	-143,588
Comprehensive Net Income	-143,498
Economic Capital Ratio	140%